20. Wakix

FDA Building 2

Active ingredient: pitolisant
Disease: narcolepsy
Peak sales estimate: n/a
Approved: Aug. 15, 2019
Company: Harmony Biosciences

The scoop: Pennsylvania-based Harmony Biosciences spent two years prepping and building up its infrastructure for its first-ever drug launch, and this year it scored approval for Wakix, the only narcolepsy drug that’s not a scheduled substance, executives told FiercePharma. France’s Bioprojet originally developed the drug and launched it in Europe after a 2016 approval there. Harmony acquired U.S. rights to the drug in the fall of 2017 and at the time raised $270 million in equity financing. Earlier this year, Harmony secured a $200 million debt facility to further support the rollout. Along the way, Harmony has established an in-house sales force, a medical science liaison team, a market access team and more. Wakix will challenge another 2019 approval in Jazz’s Sunosi, plus Jazz’s established Xyrem and other narcolepsy options. — Eric Sagonowsky

20. Wakix

Suggested Articles

Antonio Gualberto, M.D., Ph.D., helped found Kura Oncology and ran its R&D as CMO. Now, he’s moving over to fill the same role at H3 Biomedicine.

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

The deal will see GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.